5 Key Takeaways

• 1

  Semaglutide may safely and effectively reduce metabolic dysfunction–associated steatotic liver disease severity in HIV patients.

• 2

  The study involved 49 patients, 82% of whom were on antiretroviral therapy with integrase strand transfer inhibitors.

• 3

  After 24 weeks, semaglutide reduced liver fat by 31%, with 29% of patients achieving complete resolution of their liver disease.

• 4

  Patients also experienced weight loss and reductions in fasting blood glucose and triglycerides during the study.

• 5

  Common adverse events included nausea, diarrhea, vomiting, and abdominal pain among those taking semaglutide.